Mesoblast Limited

(NASDAQ:MESO)

Latest On Mesoblast Limited (MESO):

Date/Time Type Description Signal Details
2023-05-26 06:19 ESTNewsMesoblast Limited (MESO) Q3 2023 Earnings Call TranscriptN/A
2023-05-26 06:19 ESTNewsMesoblast GAAP EPS of -$0.025 beats by $0.13, revenue of $1.94M misses by $0.18MN/A
2023-05-04 20:51 ESTNewsMesoblast Has A Strong Upside PotentialN/A
2023-03-08 20:50 ESTNewsMesoblast stock surges ~10% on getting FDA review of graft versus host disease therapyN/A
2023-03-02 11:37 ESTNewsMesoblast Limited. (MESO) Q2 2023 Earnings Call TranscriptN/A
2023-02-28 14:47 ESTNewsMesoblast Limited 2023 Q2 - Results - Earnings Call PresentationN/A
2022-12-23 19:10 ESTNewsMesoblast and Oaktree extend availability of undrawn facilityN/A
2022-12-06 13:18 ESTNewsMesoblast stock falls 10% as Jefferies cuts rating to HoldN/A
2022-11-24 00:38 ESTNewsMesoblast Limited (MESO) Q1 2023 Earnings Call TranscriptN/A
2022-11-23 07:29 ESTNewsMesoblast GAAP EPS of -$0.0243 beats by $0.14, revenue of $1.5M misses by $1.82MN/A
2022-10-31 12:34 ESTNewsMesoblast reports operational and financial highlights for Q3N/A
2022-08-31 07:31 ESTNewsMesoblast Limited 2022 Q4 - Results - Earnings Call PresentationN/A
2022-08-31 07:31 ESTNewsMesoblast Limited (MESO) Q4 2022 Earnings Call TranscriptN/A
2022-08-31 07:31 ESTNewsMesoblast GAAP EPS of -$0.14, revenue of $10.21MN/A
2022-06-01 09:26 ESTNewsMesoblast GAAP EPS of -$0.03, revenue of $2MN/A
2022-02-02 13:18 ESTNewsNew medical chief at MesoblastN/A
2022-01-12 16:28 ESTNewsMesoblast’s rexlemestrocel-L results in durable pain reduction in degenerative disc diseaseN/A
2021-12-31 16:22 ESTNewsMesoblast to provide new data to FDA to support remestemcel-L BLA resubmissionN/A
2021-12-16 20:12 ESTNewsFDA’s OTAT in agreement pain reduction as primary endpoint in Mesoblast's Phase 3 programN/A
2021-12-14 07:58 ESTNewsMesoblast falls 8% after Novartis terminates deal prior to closingN/A
2021-12-06 08:59 ESTNewsMesoblast's rexlemestrocel-L shows treatment benefit in cardiovascular events in heart patientsN/A
2021-11-24 11:49 ESTNewsMesoblast EPS beats by $0.10, beats on revenueN/A
2021-11-22 16:32 ESTNewsMesoblast and Oaktree Capital refinance senior debt facilityN/A
2021-11-15 18:27 ESTNewsMesoblast's rexlemestrocel-l shows reduction in cardiovascular mortality, heart attacks and strokesN/A
2021-08-31 00:59 ESTNewsMesoblast EPS beats by $0.38N/A
2021-07-22 15:51 ESTNewsMesoblast reports FQ3 resultsN/A
2021-07-22 15:48 ESTNewsMesoblast provides update on rexlemestrocel-L in development for low back painN/A
2021-07-22 15:47 ESTNewsMesoblast reports respiratory function results of COVID-19 ARDS trialN/A
2021-07-22 15:47 ESTNewsMesoblast presents data showing mortality reduction of COVID-19 therapyN/A
2021-05-01 01:30 ESTNewsMESO, MOTS and SALM among premarket gainersN/A
2021-04-30 03:28 ESTNewsMesoblast's remestemcel-L reduces mortality by 46% in patients under age 65 with COVID-19 ARDSN/A
2021-04-08 03:05 ESTNewsMaxim upgrades Mesoblast to buy, sets $18 price targetN/A
2021-03-17 15:22 ESTAnalyst RatingThe Analyst Target Price has decreased from $14.5 to $13.7.Neutral
2021-03-16 23:50 ESTAnalyst RatingThe Analyst Target Price has decreased from $14.96 to $14.5.Neutral
2021-03-03 00:44 ESTNewsMesoblast announces a private placement of $110 millionN/A
2021-03-01 01:44 ESTEarnings EstimateAn EPS average of $0.03 is estimated for the quarter ending on March 31, 2021.Buy
2021-02-28 05:42 ESTFinancialsCompany financials have been released.Neutral
2021-02-17 14:54 ESTNewsMesoblast gains as remestemcel-l shows positive action in MIS-C post COVID-19N/A
2021-02-15 13:38 ESTAnalyst RatingThe Analyst Target Price has increased from $14.29 to $14.96.Buy
2021-02-12 12:18 ESTNewsMesoblast announces data from Phase 3 study in chronic back painN/A
2021-01-29 11:38 ESTNewsMesoblast issues FQ2 operational and financial updateN/A
2021-01-27 14:09 ESTAnalyst RatingThe Analyst Target Price has decreased from $14.96 to $14.29.Neutral
2021-01-19 22:20 ESTNewsMesoblast's Time May Be UpN/A
2021-01-11 12:34 ESTNewsMesoblast's rexlemestrocel-l reduces heart attacks, strokesN/A
2020-12-25 10:33 ESTAnalyst RatingThe Analyst Target Price has decreased from $16.45 to $14.96.Neutral
2020-12-24 16:56 ESTNewsMesoblast: The Future Looks BleakN/A
2020-12-24 02:40 ESTAnalyst RatingThe Analyst Target Price has increased from $14.96 to $16.45.Buy
2020-12-23 18:45 ESTAnalyst RatingThe Analyst Target Price has decreased from $15.39 to $14.96.Neutral
2020-12-20 22:34 ESTAnalyst RatingThe Analyst Target Price has decreased from $16.82 to $15.39.Neutral
2020-12-18 05:21 ESTNewsMesoblast shares plunge 32% after stem-cell therapy not likely to meet target for reducing mortality due to COVID-19N/A

About Mesoblast Limited (MESO):

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.

MESO Quotes by TradingView

See Advanced Chart

General

  • Name Mesoblast Limited
  • Symbol MESO
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 102
  • Fiscal Year EndJune
  • IPO Date2015-11-13
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.mesoblast.com
View More

Valuation

  • Forward PE 454.55
  • Price/Sales (Trailing 12 Mt.) 62.46
  • Price/Book (Most Recent Quarter) 2.28
  • Enterprise Value Revenue 70.47
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.29
  • Next Year EPS Estimate $0.17
  • Operating Margin -682%
  • Return on Assets -10%
  • Return on Equity -19%
  • Revenue 16.45 million
  • Earnings Per Share -$0.91
  • Revenue Per Share $0.15
  • Gross Profit 6.85 million
  • Quarterly Earnings Growth 1.6%
View More

Highlights

  • Market Capitalization 1.26 billion
  • EBITDA -78815000
  • Analyst Target Price $13.7
  • Book Value Per Share $4.42
View More

Share Statistics

  • Shares Outstanding 129.62 million
  • Shares Float 101.69 million
  • % Held by Insiders <1%
  • % Held by Institutions 2.87%
  • Shares Short 1.88 million
  • Shares Short Prior Month 2.82 million
  • Short Ratio 4.29
  • Short % of Shares Outstanding 2%
View More

Technicals

  • Beta 2.71
  • 52 Week High $21.28
  • 52 Week Low $3.12
  • 50 Day Moving Average 9.64
  • 200 Day Moving Average 12.23
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Mesoblast Limited (MESO) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Mesoblast Limited (MESO) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-26$N/A-$0.22-$0.15-43.61%
2020-09-302020-11-19$N/A-$0.21-$0.2619.04%
2020-06-302020-08-26$N/A-$0.30-$0.21-42.52%
2020-03-312020-05-27$12.08 million-$0.14-$0.1612.62%
2019-12-312020-02-26$2.21 million-$0.23-$0.13-71.64%
2019-09-302019-11-25$16.87 million-$0.06-$0.1970.27%
2019-06-302019-08-29$1.25 million-$0.21-$0.2724.04%
2019-03-312019-05-30$1.25 million-$0.25-$0.263.85%
2018-12-312019-02-20$1.87 million-$0.25-$0.23-8.7%
2018-09-302018-11-15$11.64 million-$0.20-$0.2311.52%
2018-06-302018-08-29$1.7 million-$0.22-$0.232.19%
2018-03-312018-05-30$1.07 million-$0.22-$0.22-1.59%
2017-12-312018-02-27$13.28 million$0.15-$0.20172.03%
2017-09-302017-11-14$1.11 million-$0.08-$0.2467.21%
2017-06-302017-08-29$473000-$0.32-$0.21-50.59%
2017-03-312017-05-24$820000-$0.12-$0.1935.26%
2016-12-312017-02-26$433000-$0.26-$0.20-34.92%
2016-09-302016-11-14$218000-$0.05-$0.2175.05%
2016-06-302016-08-24$26.62 million$0.64-$0.20423.54%
2016-03-312016-05-09$3.85 million-$0.04-$0.1263.7%
2015-12-312016-02-16$3.75 million-$0.31-$0.17-80.75%
2015-09-302015-12-16$7.25 million-$0.19

Mesoblast Limited (MESO) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Apr 30 2020 Mar 31 2020
Research Development N/A N/A N/A N/A 14.38 million
Income Before Tax N/A N/A N/A N/A -17.22 million
Selling General Administrative N/A N/A N/A N/A 5.73 million
Gross Profit N/A N/A N/A N/A N/A
Ebit N/A N/A N/A N/A -12.54 million
Operating Income N/A N/A N/A N/A -15.64 million
Income Tax Expense 74000 -730000 -3.26 million -3.26 million -1.96 million
Total Revenue N/A N/A N/A N/A 12.08 million
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A N/A N/A N/A 2.04 million
Net Income From Continuing Operations N/A N/A N/A N/A -15.26 million
Net Income Applicable to Common Shares -25.69 million -24.54 million -32.61 million -32.61 million -15.26 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Apr 30 2020 Mar 31 2020 Jan 31 2020
Investments -81000 -1.87 million -1.87 million -693000 -693000
Change to Liabilities N/A N/A 6.2 million 403000 403000
Total Cash Flow from Investing Activities N/A N/A -1.87 million -693000 -693000
Net Borrowings N/A N/A -406000 -524000 -524000
Total Cash Flow from Financial Activities 6.54 million 88.92 million 88.92 million -65000 -65000
Change to Operating Activities N/A N/A 2.54 million -6.51 million -6.51 million
Change in Cash N/A 67.47 million 67.47 million -20.65 million -20.65 million
Total Cash from Operating Activities N/A N/A -19.58 million -19.9 million -19.9 million
Depreciation N/A N/A N/A 946000 946000
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A 64000 64000
Other Cash Flow from Financing Activities N/A N/A -4.07 million -47000 -47000
Change to Net Income N/A N/A 1.84 million 463000 463000
Capital Expenditures 81000 841000 841000 693000 693000
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Apr 30 2020 Mar 31 2020
Total Liabailities N/A N/A N/A N/A 177.98 million
Total Stockholder Equity N/A N/A N/A N/A 487.81 million
Other Current Liabilities 18.31 million 22.22 million N/A N/A N/A
Total Assets N/A N/A N/A N/A 665.79 million
Common Stock 1.07 billion 1.06 billion 1.05 billion N/A 960.45 million
Other Current Assets N/A N/A N/A 1.05 billion N/A
Retained Earnings -598.99 million -573.3 million -548.76 million -548.76 million -516.15 million
Other Liabilities 21.94 million 23.22 million 30.79 million 30.79 million 35.58 million
Other Assets 3.21 million 3.33 million 3.31 million 3.31 million 3.24 million
Cash N/A N/A N/A N/A 60.08 million
Total Current Liabilities 91.04 million 87.7 million N/A N/A 76.69 million
Other Stockholder Equity 52.19 million 48.8 million 46.63 million 46.63 million 43.51 million
Property, Plant & Equipment 10.41 million 10.33 million 10.27 million 10.27 million 9.44 million
Total Current Assets 90.46 million 115.74 million N/A N/A 69.39 million
Long Term Investments N/A N/A N/A N/A 1.77 million
Net Tangible Assets -62.6 million -42.71 million -32.28 million -32.28 million -94.13 million
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt N/A N/A N/A N/A 59.95 million
Inventory N/A N/A N/A N/A N/A
Accounts Payable 28.61 million 27.6 million N/A N/A 19.48 million

Mesoblast Limited (MESO) Chart:

Mesoblast Limited (MESO) News:

Below you will find a list of latest news for Mesoblast Limited (MESO) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Mesoblast Limited (MESO) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-06-2050CALL0 0836.8TRUE00
2025-06-2060CALL0 0163.08TRUE00
2025-06-2070CALL0 0381.19TRUE00
2025-06-2080CALL0 0425.39TRUE00
2025-06-2090CALL0 2100.82TRUE00
2025-06-20101.45CALL0 15193.79TRUE00
2025-06-20110CALL0 2108.1FALSE00
2025-06-20121CALL0 15145.04FALSE00
2025-06-20130.2CALL30 8295.68FALSE0.20
2025-06-20140.2CALL0 295.71FALSE00
2025-06-20150CALL0 5182.25FALSE00
2025-06-20160.1CALL0 1097.46FALSE00
2025-06-20170CALL0 0454.06FALSE00
2025-06-20200.05CALL0 4502.09FALSE00
2025-06-2050PUT0 0852.39FALSE00
2025-06-2060PUT0 0695.97FALSE00
2025-06-2070PUT0 0576.94FALSE00
2025-06-2080PUT0 0310.86FALSE00
2025-06-2090.24PUT0 1200.27FALSE00
2025-06-20100.7PUT0 10163.89FALSE00
2025-06-20110PUT0 102170.95TRUE00
2025-06-20120PUT0 2487.89TRUE00
2025-06-20130PUT0 21350.11TRUE00
2025-06-20140PUT0 4199.55TRUE00
2025-06-20150PUT0 1311.95TRUE00
2025-06-20160PUT0 1298.56TRUE00
2025-06-20170PUT0 0407.63TRUE00
2025-06-20200PUT0 00TRUE00
2025-07-1830CALL0 0797.32TRUE00
2025-07-1850CALL0 2466.38TRUE00
2025-07-1860CALL0 0344.99TRUE00
2025-07-1873.65CALL0 60294.66TRUE00
2025-07-1880CALL0 61113.32TRUE00
2025-07-1892.01CALL0 75101.92TRUE00
2025-07-18101.2CALL0 47971.27TRUE00
2025-07-18111.43CALL0 4587.48FALSE00
2025-07-18120.9CALL0 643142.93FALSE00
2025-07-18130CALL0 15380.23FALSE00
2025-07-18140CALL0 86154.28FALSE00
2025-07-18150CALL0 2287137.44FALSE00
2025-07-18160CALL0 1177145.57FALSE00
2025-07-18170CALL0 101166.18FALSE00
2025-07-18180CALL0 170170.2FALSE00
2025-07-18190CALL0 506175.15FALSE00
2025-07-18200.2CALL0 5589165.82FALSE00
2025-07-18210CALL0 18166.02FALSE00
2025-07-18220CALL0 81185.02FALSE00
2025-07-18230CALL0 108186.86FALSE00
2025-07-18240CALL0 5213129FALSE00
2025-07-18250CALL0 29191.2FALSE00
2025-07-18260CALL0 7351.51FALSE00
2025-07-18270CALL0 155357.42FALSE00
2025-07-18280CALL0 1363.05FALSE00
2025-07-18290CALL0 0368.41FALSE00
2025-07-18300CALL0 45373.53FALSE00
2025-07-18310CALL0 1378.43FALSE00
2025-07-18320CALL0 8383.13FALSE00
2025-07-18330CALL0 4387.64FALSE00
2025-07-18340CALL0 2391.98FALSE00
2025-07-18350CALL0 2396.16FALSE00
2025-07-1830PUT0 0962.29FALSE00
2025-07-1850PUT0 2525.52FALSE00
2025-07-1860PUT0 8429.19FALSE00
2025-07-1870PUT0 9202.94FALSE00
2025-07-1880PUT0 0203.27FALSE00
2025-07-1890PUT0 12154.05FALSE00
2025-07-18101PUT20 49689.26FALSE-0.05-0.05
2025-07-18110PUT0 5275.85TRUE00
2025-07-18122.1PUT0 13106.02TRUE00
2025-07-18130PUT0 41107.24TRUE00
2025-07-18140PUT0 40111.54TRUE00
2025-07-18150PUT0 1124112.48TRUE00
2025-07-18160PUT0 25128.46TRUE00
2025-07-18170PUT0 19125TRUE00
2025-07-18180PUT0 589110.82TRUE00
2025-07-18190PUT0 0118.79TRUE00
2025-07-18209.55PUT0 33151.02TRUE00
2025-07-18210PUT0 10140.39TRUE00
2025-07-18220PUT0 0120.34TRUE00
2025-07-18230PUT0 0137.2TRUE00
2025-07-18240PUT0 0194.35TRUE00
2025-07-18250PUT0 3157.4TRUE00
2025-07-18260PUT0 0190.01TRUE00
2025-07-18270PUT0 0201.15TRUE00
2025-07-18280PUT0 0206.35TRUE00
2025-07-18290PUT0 0199.31TRUE00
2025-07-18300PUT0 0172.24TRUE00
2025-07-18310PUT0 0226.33TRUE00
2025-07-18320PUT0 0190.34TRUE00
2025-07-18330PUT0 0184.51TRUE00
2025-07-18340PUT0 0188.32TRUE00
2025-07-18350PUT0 0202TRUE00
2025-10-1730CALL0 0164.77TRUE00
2025-10-1750CALL0 52275.47TRUE00
2025-10-1764.8CALL0 24210.5TRUE00
2025-10-1770CALL0 1572.94TRUE00
2025-10-1780CALL0 12987.26TRUE00
2025-10-1790CALL0 378.35TRUE00
2025-10-17102.6CALL55 70890.87TRUE-0.08-0.03
2025-10-17112.2CALL130 5990.84FALSE2.20
2025-10-17121.9CALL236 188692.33FALSE1.90
2025-10-17131.75CALL160 30397.61FALSE1.750
2025-10-17141.38CALL58 41992.6FALSE0.080.06
2025-10-17151.15CALL179 39091.53FALSE0.090.08
2025-10-17160.95CALL0 1039109.99FALSE00
2025-10-17170.85CALL0 17596.68FALSE00
2025-10-17180.77CALL6 14594.27FALSE0.770
2025-10-17190.72CALL0 16898.52FALSE00
2025-10-17200.66CALL0 3233126.99FALSE00
2025-10-17210CALL0 25119.59FALSE00
2025-10-17220CALL0 8119.23FALSE00
2025-10-17230CALL0 200119.58FALSE00
2025-10-17250CALL0 3119.04FALSE00
2025-10-17300CALL0 3133.8FALSE00
2025-10-1730PUT0 0560.88FALSE00
2025-10-1750PUT0 0149.53FALSE00
2025-10-1760.35PUT0 27588.31FALSE00
2025-10-1770PUT0 0131.99FALSE00
2025-10-1780PUT0 25120.12FALSE00
2025-10-1790PUT0 291.65FALSE00
2025-10-17102PUT0 22578.2FALSE00
2025-10-17112.45PUT0 1487.21TRUE00
2025-10-17123.2PUT30 177193.07TRUE-0.2-0.06
2025-10-17134.2PUT0 1683.03TRUE00
2025-10-17145PUT0 1698.79TRUE00
2025-10-17150PUT0 206107.46TRUE00
2025-10-17160PUT0 0105.03TRUE00
2025-10-17170PUT0 0114.05TRUE00
2025-10-17180PUT0 0100.74TRUE00
2025-10-17190PUT0 0132.56TRUE00
2025-10-17209.9PUT0 33114.02TRUE00
2025-10-17210PUT0 0111.71TRUE00
2025-10-17220PUT0 099.46TRUE00
2025-10-17230PUT0 0123.13TRUE00
2025-10-17250PUT0 00TRUE00
2025-10-17300PUT0 0133.97TRUE00
2026-01-160.50CALL0 200TRUE00
2026-01-1610CALL0 100TRUE00
2026-01-161.50CALL0 00TRUE00
2026-01-1620CALL0 1000TRUE00
2026-01-162.50CALL0 12610TRUE00
2026-01-1630CALL0 0138.02TRUE00
2026-01-1640CALL0 100TRUE00
2026-01-1650CALL0 066.86TRUE00
2026-01-1660CALL0 0161.43TRUE00
2026-01-1675.22CALL0 2697.53TRUE00
2026-01-1680CALL0 081.07TRUE00
2026-01-1690CALL0 078.73TRUE00
2026-01-16102.95CALL13 080.36TRUE2.950
2026-01-16110CALL0 083.03FALSE00
2026-01-16122.44CALL100 6386.68FALSE2.440
2026-01-16130CALL0 081.96FALSE00
2026-01-16142CALL0 16101.48FALSE00
2026-01-16151.71CALL100 6387.18FALSE1.710
2026-01-16160CALL0 094.2FALSE00
2026-01-16170CALL0 085.41FALSE00
2026-01-16201.5CALL0 796.65FALSE00
2026-01-160.50PUT0 0343.62FALSE00
2026-01-1610PUT0 0236.05FALSE00
2026-01-161.50PUT0 0189.92FALSE00
2026-01-1620PUT0 20161.02FALSE00
2026-01-162.50PUT0 0158.33FALSE00
2026-01-1630PUT0 0439.76FALSE00
2026-01-1640PUT0 0153.53FALSE00
2026-01-1650PUT0 0234.88FALSE00
2026-01-1660PUT0 0192.24FALSE00
2026-01-1670PUT0 0110.51FALSE00
2026-01-1681.5PUT0 696.44FALSE00
2026-01-1690PUT0 1795.88FALSE00
2026-01-16103.8PUT0 090.11FALSE00
2026-01-16110PUT0 0100.09TRUE00
2026-01-16120PUT0 089.37TRUE00
2026-01-16130PUT0 086.27TRUE00
2026-01-16145.4PUT0 497.22TRUE00
2026-01-16150PUT0 095.12TRUE00
2026-01-16160PUT0 098.34TRUE00
2026-01-16170PUT0 0108.65TRUE00
2026-01-16200PUT0 099.19TRUE00
2030-12-18100.2CALL456 3400TRUE-3.3-0.94
2030-12-18250PUT 0TRUE00

Latest MESO Trades:

Date Shares Price
Jun 13, 2022 7:54 PM EST100$2.645
Jun 13, 2022 7:54 PM EST100$2.645
Jun 13, 2022 7:55 PM EST100$2.64
Jun 13, 2022 7:57 PM EST186$2.66
Jun 13, 2022 7:57 PM EST14$2.66

Mesoblast Limited (MESO) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020031530/0001564590-20-031530-index.htm
2020-01-30SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1345099/000119312520019148/0001193125-20-019148-index.htm
2020-07-27S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1345099/000121390020018628/0001213900-20-018628-index.htm
2020-05-26DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1345099/000134509920000001/0001345099-20-000001-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1345099/000142284920000077/0001422849-20-000077-index.htm
2019-09-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019034209/0001564590-19-034209-index.htm
2019-09-0920-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1345099/000156459019034304/0001564590-19-034304-index.htm
2019-09-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019034483/0001564590-19-034483-index.htm
2019-10-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019036315/0001564590-19-036315-index.htm
2019-10-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019036431/0001564590-19-036431-index.htm
2019-10-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019036737/0001564590-19-036737-index.htm
2019-10-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019037256/0001564590-19-037256-index.htm
2019-11-016-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019039260/0001564590-19-039260-index.htm
2019-11-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019041204/0001564590-19-041204-index.htm
2019-11-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019044600/0001564590-19-044600-index.htm
2019-11-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019044601/0001564590-19-044601-index.htm
2019-11-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019044825/0001564590-19-044825-index.htm
2019-12-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019045775/0001564590-19-045775-index.htm
2019-12-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019046754/0001564590-19-046754-index.htm
2020-01-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020000984/0001564590-20-000984-index.htm
2020-01-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020001658/0001564590-20-001658-index.htm
2020-02-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020003090/0001564590-20-003090-index.htm
2020-02-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020003512/0001564590-20-003512-index.htm
2020-02-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020004688/0001564590-20-004688-index.htm
2020-02-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020006501/0001564590-20-006501-index.htm
2020-02-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020007597/0001564590-20-007597-index.htm
2020-03-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020009861/0001564590-20-009861-index.htm
2020-03-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020011865/0001564590-20-011865-index.htm
2020-03-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020012613/0001564590-20-012613-index.htm
2020-04-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020014830/0001564590-20-014830-index.htm
2020-04-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020015584/0001564590-20-015584-index.htm
2020-04-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020016005/0001564590-20-016005-index.htm
2020-04-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020017344/0001564590-20-017344-index.htm
2020-04-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020018322/0001564590-20-018322-index.htm
2020-05-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020020611/0001564590-20-020611-index.htm
2020-05-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020022226/0001564590-20-022226-index.htm
2020-05-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020025586/0001564590-20-025586-index.htm
2020-05-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020026055/0001564590-20-026055-index.htm
2020-05-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020026914/0001564590-20-026914-index.htm
2020-05-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020027408/0001564590-20-027408-index.htm
2020-05-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020027410/0001564590-20-027410-index.htm
2020-06-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020028116/0001564590-20-028116-index.htm
2020-06-186-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020029698/0001564590-20-029698-index.htm
2020-06-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020030668/0001564590-20-030668-index.htm
2020-07-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020031530/0001564590-20-031530-index.htm
2020-07-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020031863/0001564590-20-031863-index.htm
2020-07-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020032147/0001564590-20-032147-index.htm
2020-07-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020033456/0001564590-20-033456-index.htm
2020-08-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020035263/0001564590-20-035263-index.htm
2020-08-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020038657/0001564590-20-038657-index.htm
2020-08-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020039445/0001564590-20-039445-index.htm
2020-08-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020040358/0001564590-20-040358-index.htm
2020-08-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020041082/0001564590-20-041082-index.htm
2020-08-316-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020041869/0001564590-20-041869-index.htm
2020-09-0320-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1345099/000156459020042401/0001564590-20-042401-index.htm
2020-09-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020042407/0001564590-20-042407-index.htm
2020-09-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020042713/0001564590-20-042713-index.htm
2020-09-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020043641/0001564590-20-043641-index.htm
2020-09-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020043751/0001564590-20-043751-index.htm
2020-10-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020045777/0001564590-20-045777-index.htm
2020-10-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020046432/0001564590-20-046432-index.htm
2020-10-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020047335/0001564590-20-047335-index.htm
2020-10-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020048488/0001564590-20-048488-index.htm
2020-11-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020049709/0001564590-20-049709-index.htm